Epstein-Barr virus and gastric carcinoma

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Epstein-Barr virus (EBV) is an established cause of gastric carcinoma (GC), accounting for approximately 10% of cases.
• EBV-associated GC arises from monoclonal growth of infected epithelial cells exhibiting a latency I program.
• Histological hallmarks include a distinctive "lace pattern" and immune cell infiltration.

Purpose of the Study:

• To elucidate the molecular mechanisms by which EBV contributes to gastric carcinogenesis.
• To investigate the role of specific EBV-encoded proteins in the epigenetic alterations observed in EBV-associated GC.
• To understand the cellular pathways targeted by EBV for promoting tumor development.

Main Methods:

• Utilized EBV encoded small RNA (EBER)-in situ hybridization to trace EBV infection progression in gastric mucosa.
• Employed recombinant EBV infection systems with gastric cancer cell lines.
• Investigated the impact of viral latent membrane protein 2A (LMP2A) on DNA methylation and cellular signaling pathways (STAT3, DNMT1, PTEN).

Main Results:

• EBV infection leads to global, non-random CpG island methylation in cancer-related genes.
• Viral LMP2A was identified as the key driver of DNA methylation promotion in EBV-associated GC.
• LMP2A upregulates DNMT1 via STAT3 phosphorylation, resulting in PTEN tumor suppressor gene methylation.

Conclusions:

• EBV-associated GC development involves epigenetic dysregulation driven by viral factors.
• LMP2A plays a critical role in inducing aberrant DNA methylation, contributing to oncogenesis.
• The cellular response to EBV infection, including heightened DNA methylation, may paradoxically promote cancer development.